---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-349141"
form_type: "8-K"
ticker: "KYNB"
cik: "0000921299"
company_name: "KYNTRA BIO, INC."
filed_at: "2026-08-13T20:05:16+00:00"
generated_at: "2026-08-13T20:07:19.014604+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Kyntra Bio Q2 2026 net income $12M vs year-ago loss; cash $95.7M, runway to 2028

## Summary
- Net income from continuing ops $12.0M ($2.96/share) vs net loss $13.7M ($3.38/share) in Q2 2025.
- Total revenue from continuing ops was negative $1.5M vs positive $1.3M in Q2 2025.
- Cash, cash equivalents, investments, and accounts receivable $95.7M as of June 30, 2026; expected to fund operations into 2028.
- FG-3246 Phase 2 interim analysis in mCRPC on track for 4Q 2026; roxadustat Phase 3 protocol finalized, initiation targeted 4Q 2026.
- New MATTERHORN post hoc data at EHA 2026 showed transfusion independence benefit in LR-MDS with HTB.

## SEC filing metadata
- accession: 0001193125-26-349141
- form_type: 8-K
- ticker: KYNB
- cik: 0000921299
- company_name: KYNTRA BIO, INC.
- filed_at: 2026-08-13T20:05:16+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/921299/000119312526349141/0001193125-26-349141-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/921299/000119312526349141/kynb-20260813.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-349141
- JSON: https://secwatch.observer/filing/0001193125-26-349141.json
- Plain text: https://secwatch.observer/filing/0001193125-26-349141.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.